"Multispan performs GPCR screening for us on a battery of 32 typical targets and off-target GPCRs in drug discovery. What is most impressive about their work product is that they determine functionality (agonist, partial agonist and antagonist) and potency from dose-response curves using multiplexing of assays. After comparison between vendors, we found Multispan to be the least expensive option and to provide the greatest value for the funds we have available. The post-assay customer interface is excellent in that they answer questions and provide relevant commentary as needed."
Allen Reitz, Ph.D.
Chief Executive Officer, Fox Chase Therapeutics Discovery, Inc.
